Spots Global Cancer Trial Database for Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

Official Title: An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer

Study ID: NCT02140437

Conditions

Carcinoma Breast Stage IV

Interventions

Fulvestrant

Anastrozole

Study Description

Brief Summary: This research is designed to investigate whether the addition of fulvestrant 500mg to anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced breast cancer.

Detailed Description: Anastrozole is the standard first-line endocrine treatment for patients with hormonal receptor positive advanced breast cancer. It has been proven that the addition of fulvestrant 250mg can enhance PFS of anastrozole monotherapy according to SWOG0226 study. However, the optimal recommended dose of fulvestrant for patients with advanced breast cancer is 500mg worldwide according to CONFIRM study. The investigator designed this research to investigate whether high dose fulvestrant can further improve efficacy of anastrozole monotherapy.